Connect with us

American Cannabis News

Curaleaf Q2 Revenue Falls 8% – New Cannabis Ventures

Published

on

Curaleaf Q2 Revenue Falls 8% – New Cannabis Ventures

Curaleaf reports 2025 results of the second quarter. Internal stabilization, strong international momentum
  • The second quarter 2025 total income of $ 315 million
  • The second quarter of 2025 international income, $ 41 million
  • The second quarter 2025 adjusted gross margin 49%
  • He was awarded at the NASCENT MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTIONAL MESTION

Stamford, Conn., 6, 2025 / PRNEWSWIRE / – Curaleaf Holdings, Inc. (TSX: Cura) (otcqx: Curaleaf or Curaleaf, the leading international supplier of consumer goods at Cannabis, reports that it is planned for the last second quarter, unless otherwise stated.

Kuralef President and Chief Executive Director Boris Jordan, the income of the second quarter, compared to the first quarter, was 66 million dollars for the previous quarter. Growth We ended Q2 with $ 102 million in cash, $ 47 million, and debt payment. “

Mr. Jordan continued. The growth. Through the collection of assets built and the asset database, we are now tightening our attention to the quality of the quality of the product, customer service and chain of excellence.

Second quarter 2025 Financial importance

  • A net income worth $ 314.5 million, a year annually, is 8% compared to 342.3 million dollars in the quarter of 8224. Sequential, net income increased by 1.5% compared to 310.0 million US dollars in 2025
  • Gross profit: $ 152.6 million and gross margin, 49%, 160 basic points per year
  • Adjusted gross profit of $ 153.5 million and adjusted gross margin (1) 49%, 120 base scores increase
  • Net loss attributed to Curaleaf Holdings, Inc. $ 50.6 million or net loss from one share of $ 0.07 on continuous activities
  • Adjusted net losses from $ 47.8 million to one share of $ 0.06 per share
  • Adjusted eBitda¹ is $ 65.5 million
  • At the end of the quarter was $ 102.3 million

Original press release

Published by NCV NewsWire

NCV NewsWire:

NCV NewsWire aims to treat high-quality content and information about cannabis companies by New Cannabis Ventures to help our readers make noise and remain the most important cannabical business news. NCV Newswire is hand treated by hand and is not automated. Have secret news tip. Contact:A number

Get our Sunday newsletter





American Cannabis News

Vireo Growth Is Now the 7th Largest MSO by Revenue – New Cannabis Ventures

Published

on

By

Vireo Growth Is Now the 7th Largest MSO by Revenue – New Cannabis Ventures

Vireo Growth Inc. Announces Fourth Quarter 2025 Results
  • Q4 GAAP revenue of $104.5 million was up 317.7% year-over-year, driven by recently closed M&A deals.
  • In Q4, same-store sales were up 22% year-over-year and wholesale revenue was up 55% year-over-year; Excluding Minnesota, same-store sales rose 11.3% year-over-year
  • Announced pending acquisitions of Eaze, Schwazze and PharmaCann retail assets in Colorado, as well as an MOU for the Hawthorne acquisition, all of which are expected to close in the first half of 2026.
  • The company closed the fourth quarter with $122.5 million in cash; expects to remain obtainable

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary form, with accompanying commentary and from management of certain key operating metrics that the Company uses to evaluate its performance. All currency figures shown here are in US dollars.

Management Commentary

Chief Executive Officer John Mazarakis commented: “Fourth quarter performance remained in line with our expectations and reflected same-store sales growth excluding Minnesota’s 11.3% increase and wholesale’s 55% increase in the year-ago quarter. As we begin the new year, we will continue to optimize all areas of our business while maintaining opportunities for further growth.

Recent developments

On December 16, 2025, the Company entered into an asset purchase agreement through a wholly-owned subsidiary to acquire certain assets and property used in a cannabis dispensary operating in the state of Colorado owned by PharmaCann Inc. (“PharmaCann”). Under the terms of the agreement, the Company expects to issue subordinated voting stock with an estimated value of $49,000,000 and assume certain liabilities in exchange for the assets acquired. Stock compensation is subject to certain adjustments.

On December 22, 2025, the Company entered into a merger agreement and plan to acquire Eaze Inc. (“Eaze”) in a business combination transaction. Pursuant to the agreement, following the closing of the transaction, the Company expects to issue subordinate voting shares as consideration for the issued and outstanding shares of Eaze. The estimated closing consideration is approximately $47,000,000, subject to customary post-closing adjustments. The merger agreement also provides for the payment of potential earnings payable in subordinated voting shares of the Company based on Eaze’s future financial performance, subject to contractual restrictions.

On January 15, 2026, the Company entered into a non-binding memorandum of understanding (“MOU”) with ScottsMiracle-Gro regarding the potential acquisition of The Hawthorne Gardening Company LLC (“Hawthorne”).

At the end of the fourth quarter, the Company completed the integration of its recent acquisitions from Deep Roots, Proper, and Wholesome, including streamlined accounting, finance, human resources, insurance and procurement operations, and the implementation of a new enterprise resource planning system across the organization. As a result, the Company has already implemented corporate synergies.

Balance sheet and liquidity

As of December 31, 2025, total current assets, excluding Medicine Man Technologies Inc. (dba Schwazze) (“Schwazze”) receivables, assets held for sale and income taxes receivable, were $204.1 million, including cash of $122.5 million. Total current liabilities, excluding uncertain tax liabilities, were $71.6 million. As of December 31, 2025, the Company had a total of 1,177,624,278 shares of subordinate voting stock outstanding on a treasury method basis at a par value of $0.60 per share.

Conference call and webcast information

Vireo’s management will hold a conference call with research analysts today, March 17, 2026 at 8:00 a.m. ET (7:00 a.m. CT) to discuss its financial results for the fourth quarter ended December 31, 2025. 1-646-307-1963 (Toll Free) (International) and the conference ID number is 9471311.

A live audio webcast of this event will also be available on the Events and Presentations section of the Company’s Investor Relations website and via the following link:
https://events.q4inc.com/attendee/171708452.

About Vireo Growth Inc

Vireo was founded in 2014 as a leading medical cannabis company. Vireo is building a disciplined, strategically aligned and execution-focused platform in the industry. This strategy drives our intense local market focus while leveraging the strength of the national portfolio. We are committed to hiring industry leaders and deploying capital and talent where we believe it will deliver the most value. Vireo operates with a long-term mindset, an action bias, and an unwavering commitment to its customers, employees, shareholders, industry partners, and the communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Original press release

Published by NCV Newswire

NCV Newswire

New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not, however, automated. Got a secret news tip? Get in touch.

Get our Sunday newsletter





Continue Reading

aawh

Michigan Cannabis Sales Bounced Mildly – New Cannabis Ventures

Published

on

By

Michigan Cannabis Sales Bounced Mildly – New Cannabis Ventures

Michigan hemp sales for february decreased compared to a year ago, as they increased sequentially by 3.4%. Sales of $234.6 million decreased by 3.0% compared to last year.

The Michigan Cannabis Regulatory Agency breaks down sales by medical and adult use, with medical sales down 38.6% year over year to $0.4 million, down 3.8% sequentially, and adult use sales down 3.0% year over year to $234.2 million, down 3.4% sequentially.

The state breaks down sales by category and provides pricing details by category for both medical and adult;

For Adults - Use
For Adults – Use

Medical
Medical

As supply continues to expand, prices for adult flowers have plummeted. The average price of $945 a pound in January was up 1.3 percent sequentially from a record low in December and down 8.2 percent from a year ago.

Michigan hemp sales are expected to grow 82.1% to $1.79 billion in 2021, 27.9% to $2.29 billion in 2022, and 33.3% to $3.06 billion in 2023. billion In 2026, Michigan cannabis sales decreased by 5.7%.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading

American Cannabis News

Verano Q4 Exceeded Analyst Expectations – New Cannabis Ventures

Published

on

By

Verano Q4 Exceeded Analyst Expectations – New Cannabis Ventures

Verano Announces Fourth Quarter and Full Year 2025 Financial Results
  • The company delivered sequential revenue and margin improvement within guidance in the fourth quarter; closes 2025 with the top three market share positions1 in all competing categories
  • The newly announced $195 million credit facility demonstrates the Company’s ability to access lower cost capital and secure some of the industry’s most favorable terms, including maturity and prepayment flexibility and an initial interest rate of 9.5% per annum.

CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multinational cannabis company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, prepared in accordance with US Generally Accepted Accounting Principles (“US GAAP”).

Financial highlights for the fourth quarter and full year of 2025

Original press release

Published by NCV Newswire

NCV Newswire

New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not, however, automated. Got a secret news tip? Get in touch.

Get our Sunday newsletter





Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media